Our Commitment to Cardiovascular Disease Treatment
“We strive to help patients with cardiovascular diseases by developing innovative treatments. Since 2002 our cardiovascular treatments have improved outcomes of over 40 million* patients across Europe.”
We are leaders in cardiovascular disease treatment.
Our current portfolio contains treatments for cardiovascular diseases such as:
- Atrial fibrillation
- Thrombotic disorders
*40 million patients treated with olmesartan and its combinations, prasugrel, edoxaban, pravastatin in selected countries